Disease · MONDO_0005350

abdominal aortic aneurysm

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. abdominal aortic aneurysm. Diseases, record MONDO_0005350. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0005350

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: abdominal aortic aneurysm; Open Targets
Open Targets ID: MONDO_0005350; Open Targets
Other names: Aortic Aneurysm, Abdominal; Open Targets
Disease Ontology: DOID:7693; Disease Ontology
MeSH: D017544; MeSH
Highest stage of its drugs: Approval, for 1 of its 12 drugs, from TTD; Open Targets

Drugs12

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
EVANS BLUE	CHEMBL1200712	Small molecule	Approval	TTD	1	0	0	Drugs and targets
METFORMIN	CHEMBL1431	Small molecule	Phase 2/3	ClinicalTrials.gov	2	2	2	Drugs and targets
DOXYCYCLINE	CHEMBL1200699	Small molecule	Phase 2	ClinicalTrials.gov	3	3	3	Drugs and targets
CANAKINUMAB	CHEMBL1201834	Antibody	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
CYCLOSPORINE	CHEMBL160	Protein	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
PEMIROLAST	CHEMBL1201198	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
TICAGRELOR	CHEMBL398435	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
EVOLOCUMAB	CHEMBL2364655	Antibody	Early phase 1	ClinicalTrials.gov	1	1	1	Drugs and targets
ALISKIREN	CHEMBL1639	Small molecule	Unknown	ClinicalTrials.gov	1	1	1	Drugs and targets
AMLODIPINE	CHEMBL1491	Small molecule	Unknown	ClinicalTrials.gov	1	1	1	Drugs and targets

1 to 10 of 12

See all 12 drugs

Targets80

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
CACNA1C	Voltage-gated L-type calcium channel	1	Voltage-gated L-type calcium channel blocker	Unknown	https://conductscience.org/library/genes/775	Drugs and targets
CACNA1D	Voltage-gated L-type calcium channel	1	Voltage-gated L-type calcium channel blocker	Unknown	https://conductscience.org/library/genes/776	Drugs and targets
CACNA1F	Voltage-gated L-type calcium channel	1	Voltage-gated L-type calcium channel blocker	Unknown	https://conductscience.org/library/genes/778	Drugs and targets
CACNA1S	Voltage-gated L-type calcium channel	1	Voltage-gated L-type calcium channel blocker	Unknown	https://conductscience.org/library/genes/779	Drugs and targets
COXFA4	Mitochondrial complex I (NADH dehydrogenase)	1	Mitochondrial complex I (NADH dehydrogenase) inhibitor	Phase 2/3	https://conductscience.org/library/genes/4697	Drugs and targets
COXFA4L2	Mitochondrial complex I (NADH dehydrogenase)	1	Mitochondrial complex I (NADH dehydrogenase) inhibitor	Phase 2/3	https://conductscience.org/library/genes/56901	Drugs and targets
GPD2	Glycerol-3-phosphate dehydrogenase, mitochondrial	1	Mitochondrial glycerol-3-phosphate dehydrogenase inhibitor	Phase 2/3	https://conductscience.org/library/genes/2820	Drugs and targets
IL1B	Interleukin-1 beta	1	Interleukin-1 beta inhibitor	Phase 2	https://conductscience.org/library/genes/3553	Drugs and targets
MMP1	Interstitial collagenase	1	Matrix metalloproteinase-1 inhibitor	Phase 2	https://conductscience.org/library/genes/4312	Drugs and targets
MMP13	Collagenase 3	1	Matrix metalloproteinase 13 inhibitor	Phase 2	https://conductscience.org/library/genes/4322	Drugs and targets

1 to 10 of 80

See all 80 targets

Trials13

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT01756833	Non-Invasive Treatment of Abdominal Aortic Aneurysm Clinical Trial	Phase 2	261	2021-11-26	Aneurysm	DOXYCYCLINE	Its record names the disease	ClinicalTrials.gov
NCT02007252	ACZ885 for the Treatment of Abdominal Aortic Aneurysm	Phase 2	65	2016-11-21	Abdominal Aortic Aneurysm (AAA)	CANAKINUMAB	Its record names the disease	ClinicalTrials.gov
NCT04224051	Metformin for Abdominal Aortic Aneurysm Growth Inhibition	Phase 2	500		Abdominal Aortic Aneurysm	METFORMIN	Its record names the disease	ClinicalTrials.gov
NCT02225756	Cyclosporine A in Patients With Small Diameter Abdominal Aortic Aneurysms	Phase 2	360		Abdominal Aortic Aneurysm,, Small Abdominal Aortic Aneurysm	CYCLOSPORINE	Its record names the disease	ClinicalTrials.gov
NCT05361772	Low-dose Colchicine Inhibit Abdominal Aortic Aneurysm Growth Trial	Not applicable	230		Colchicine, Abdominal Aortic Aneurysm, Progression	COLCHICINE	Its record names the disease	ClinicalTrials.gov
NCT03507413	Metformin Therapy in Non-diabetic AAA Patients	Phase 2/3	170		Abdominal Aortic Aneurysm	METFORMIN	Its record names the disease	ClinicalTrials.gov
NCT00989729	Preoperative Methylprednisolone in Endovascular Aortic Repair	Not applicable	150		Abdominal Aortic Aneurysms	METHYLPREDNISOLONE	Its record names the disease	ClinicalTrials.gov
NCT02070653	The Efficacy of Ticagrelor on Abdominal Aortic Aneurysm (AAA) Expansion	Phase 2	145		Abdominal Aortic Aneurysm	TICAGRELOR	Its record names the disease	ClinicalTrials.gov
NCT00126204	Adjunctive Treatment With Doxycycline to Enhance the Durability of Endovascular Aortic Aneurysm Repair	Not applicable	75		Aortic Aneurysm	DOXYCYCLINE	Its record names the disease	ClinicalTrials.gov
NCT00538967	The Effect of Doxycycline on Matrix Metalloproteinase Expression and Activity in the Abdominal Aneurysm	Phase 2	60		Aortic Aneurysm, Abdominal	DOXYCYCLINE	Its record names the disease	ClinicalTrials.gov

1 to 10 of 13

See all 13 trials

Comparisons in its trials6

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Doxycycline vs Placebo: Number of Participants With Aneurysm Rupture	0 of 129	0 of 125	254	NCT01756833	Trial comparisons
Doxycycline vs Placebo: Number of Participants Who Died	3 of 129	4 of 125	254	NCT01756833	Trial comparisons
Doxycycline vs Placebo: Number of Participants With Surgical Intervention	13 of 129	9 of 125	254	NCT01756833	Trial comparisons
Doxycycline vs Placebo: deaths from any cause	3 of 129	4 of 125	254	NCT01756833	Trial comparisons
Doxycycline vs Placebo: serious adverse events	70 of 129	71 of 125	254	NCT01756833	Trial comparisons
ACZ885 vs Placebo: serious adverse events	2 of 31	0 of 33	64	NCT02007252	Trial comparisons

Papers from its trials10

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
32453369	RESULT	1	PubMed
25115430	RESULT	1	PubMed
18632241	RESULT	1	PubMed
41283274	DERIVED	1	PubMed
36999821	DERIVED	1	PubMed
34655683	DERIVED	1	PubMed
33957227	DERIVED	1	PubMed
33595625	DERIVED	1	PubMed
31135888	DERIVED	1	PubMed
25963302	DERIVED	1	PubMed

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0005350

GET https://conductscience.org/api/diseases/v1/MONDO_0005350/targets?page=2

API reference For AI assistants